The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
By cutting pain crises & boosting haemoglobin
Policy symposium in Hyderabad focuses on life skills education and community?driven solutions
Medical experts point to a growing body of research linking energy drinks to liver injury
ICMR-led consultation calls for stricter HFSS regulations, nutrition literacy, and healthier food environments
Panacea Biotec receives LoA from CMSS
Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume
The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials
These approvals represent a defining moment for people living with classical Hodgkin Lymphoma
Subscribe To Our Newsletter & Stay Updated
